MRNS - Marinus Pharmaceuticals, Inc.
| Previous Close | 1.2600 |
| Open | 1.2600 |
| Bid | 1.2900 x 4000 |
| Ask | 1.3200 x 900 |
| Day's Range | 1.2600 - 1.3500 |
| 52 Week Range | 0.7700 - 6.0000 |
| Volume | 795,051 |
| Avg. Volume | 1,200,182 |
| Market Cap | 70.569M |
| Beta (3Y Monthly) | 2.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9770 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.29 |
- GlobeNewswire
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
100% of evaluable patients in target dose had no relapse during the four-week follow-up period Independent objective EEG seizure analysis confirms target dose Ganaxolone.
- GlobeNewswire
Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting ganaxolone data have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in Baltimore, Maryland on December 7 and 8, 2019.
- GlobeNewswire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 400,000 shares of its common stock to a new employee, with a grant date of November 7, 2019. The stock options were granted as an inducement material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression.
- GlobeNewswire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a.
- GlobeNewswire
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that Joe Hulihan, MD, has been appointed Chief Medical Officer. Dr. Hulihan will succeed outgoing CMO, Lorianne Masuoka, MD, who is retiring from the position. “On behalf of the entire Marinus team and Board of Directors, I welcome Joe at this exciting time at Marinus and thank Lorianne for her dedicated service,” said Scott Braunstein, MD, Chief Executive Officer of Marinus.
- GlobeNewswire
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus (RSE) were presented at the Neurocritical Care Society 17th Annual Meeting in Vancouver, BC. The results were featured in an oral platform presentation by Henri Vaitkevicius M.D., investigator in the study. As previously disclosed, ganaxolone met the primary endpoint in the study with none of the 17 patients progressing to IV anesthetics within 24 hours of treatment initiation. A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic (PK) data, presented for the first time at the meeting today.
- Benzinga
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
- Benzinga
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
- GlobeNewswire
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to a new employee, with a grant date of September 12, 2019. The options have an exercise price of $1.69 per share, which is equal to the closing price of Marinus’s common stock on September 12, 2019, the date of grant. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For September 27, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Micron Technology, Inc. (NASDAQ: MU ) shares ...
- Benzinga
Marinus Shares Rip Higher On Positive Ganaxolone Midstage Data In Epileptic Seizures
The shares, which suffered a setback in late July after a failed midstage trial of Ganaxolone in postpartum depression and have not recovered much since, could see a redemption of sorts following the readout. Marinus said the Phase 2 study evaluating the intravenous formulation of Ganaxolone, a positive allosteric modulator of GABAA, in refractory status epilepticus, or RSE, met the primary endpoint, with no patients progressing to IV anesthetics within 24 hours of treatment initiation. Status epilepticus is a rare epileptic seizure of prolonged duration, lasting more than 5 minutes for convulsive seizures or 30 minutes for non-convulsive.
- GlobeNewswire
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that it has completed the top-line analysis of the open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE). Ganaxolone met the primary endpoint in the study with no patients (n=17) progressing to IV anesthetics within 24 hours of treatment initiation.
- Zacks
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
- Simply Wall St.
Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- Zacks
Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
- GlobeNewswire
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2019. “I am proud to announce that after an extensive interview process with several qualified candidates, the Board has appointed me as Chief Executive Officer of Marinus,” commented Dr. Scott Braunstein, formerly Executive Chairman of Marinus. “As Executive Chairman, the past six months have been both invigorating and challenging as I worked with the Marinus team to continue to unlock the value potential of ganaxolone.
- Motley Fool
Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
Wall Street is not sold on the latest clinical results.
- Benzinga
Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days
Marinus — a pharma company that focuses on developing therapies for epilepsy, depression and other neuropsychiatric disorders — announced results from the second part of a Phase 2 Magnolia clinical trial that evaluated intravenous ganaxolone in women with postpartum depression, or PPD. The results showed that the Hamilton Rating Scale for Depression, or HAM-D17, scores at 28 days of treatment were the same as a placebo.
- GlobeNewswire
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced intravenous (IV) ganaxolone results from Part 2 of its Phase 2 Magnolia clinical trial, evaluating IV ganaxolone followed by daily oral ganaxolone in women with postpartum depression (PPD). The results showed that, in the study, ganaxolone administered as a six-hour infusion followed by oral administration was generally safe, well-tolerated and provided clinically meaningful reductions in Hamilton Rating Scale for Depression (HAM-D17) scores at early time points of 6 hours and 24 hours after start of treatment.
- Insider Monkey
Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Simply Wall St.
Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- GlobeNewswire
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 105,000 shares of its common stock to five new employees, with a grant date of January 24, 2019. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
